Nomura Asset Management Co. Ltd. Reduces Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Nomura Asset Management Co. Ltd. lowered its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 310,938 shares of the company’s stock after selling 2,300 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries were worth $6,853,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $50,000. Ameliora Wealth Management Ltd. purchased a new position in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $66,000. IFP Advisors Inc raised its holdings in Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock valued at $88,000 after acquiring an additional 1,960 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth $104,000. Finally, Assetmark Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 1,370.3% in the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after acquiring an additional 4,851 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $15.39 on Tuesday. Teva Pharmaceutical Industries Limited has a 52-week low of $12.51 and a 52-week high of $22.80. The company has a fifty day moving average of $17.08 and a 200-day moving average of $18.11. The company has a market capitalization of $17.44 billion, a P/E ratio of -10.61, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. Bank of America dropped their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Finally, UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.